Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary CVS Caremark will add Eli Lilly’s oral obesity medicine Foundayo to its formularies on June 1, 2026. Zepbound returns as a preferred option from October 1. Both changes reverse
AstraZeneca received FDA approval on May 18, 2026, for Baxfendy, the first aldosterone synthase inhibitor cleared for adults with uncontrolled hypertension. Click here to go to our independent assessment. https://mararating.com/report/baxdrostat-for-treatment-resistant-hypertension-as-of-april-2026/The
Eli Lilly announced the acquisition of three vaccine biotechs — Curevo, LimmaTech, and Vaccine Co. — for close to $4 billion combined. The portfolio spans a Phase 2 shingles vaccine,
Summary Contingent value rights (CVRs) — conditional payments tied to regulatory approval, reimbursement milestones, or sales thresholds — have become standard practice in pharma and biotech acquisitions, with their use
Bristol Myers Squibb and Hengrui Pharma announced a wide-ranging strategic agreement on May 12, 2026, covering 13 drug programs across oncology, hematology, and immunology. BMS commits $950 million at signing
Summary Eli Lilly and Gilead Sciences have each completed multiple acquisitions since the start of 2026, making this one of the most active years for pharma M&A since at least
Summary UCB, a Belgian pharmaceutical company, has announced a $2.2 billion deal to acquire Candid Therapeutics, a startup focused on developing bispecific antibodies for autoimmune diseases. This acquisition adds to
Chiesi Acquires KalVista: A Major Move in the Rare Disease Market Summary Chiesi Group, a family-owned Italian drugmaker, has announced plans to acquire KalVista Pharmaceuticals for $1.9 billion in order
Teva’s Strategic Move: Acquiring Emalex for Potential Tourette Syndrome Treatment Access impact Teva Pharmaceutical, known for its generic drugs, is making a strategic move to expand its portfolio with the
Summary Merck & Co. recently acquired Terns Pharmaceuticals for $6.7 billion, saving almost $1 billion due to updated data on their leukemia drug TERN-701. Merck’s research team believes that this